Posted on 07/07/2024 5:50:21 PM PDT by ConservativeMind
Physician scientists found that people with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes.
"CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes and modulate the gut microbiota in beneficial ways," said Pal.
"If the positive results observed in this small trial and a previous trial with nivolumab and ipilimumab are confirmed, CBM588 could become a valuable supplement in the treatment of various cancers, particularly for patients treated with immune checkpoint inhibitors."
An estimated 44% of U.S. patients with cancer in 2018 were eligible for checkpoint inhibitor drugs.
In the single-center, Phase I trial, 30 people with metastatic kidney cancer were randomized to receive cabozantinib, an inhibitor of vascular endothelial growth factor receptor, and targeted immunotherapy nivolumab with or without CBM588 as first-line treatment. Participants' gut microbiome were analyzed via stool samples in the beginning for a baseline and then 13 weeks into treatment.
To date, many studies on lung cancer, melanoma and metastatic kidney cancer, among other diseases, have shown that the composition of the gut microbiome could predict immunotherapy outcomes for patients with cancer.
Current guidelines for metastatic renal cell carcinoma (kidney cancer) recommend that newly diagnosed patients receive either dual checkpoint inhibitor therapy or a combination of immunotherapy and tyrosine kinase inhibitor, but most patients eventually experience disease progression while on treatment.
In the trial, researchers observed an increase in the abundance of unclassified Ruminococcaceae genera, which has been linked with improved clinical outcomes with immune checkpoint inhibitors in recent studies. Clostridium butyricum MIYAIRI 588, the bacterium in CBM588, produces butyric acid, which is critical for intestinal health and is a well-known immunomodulator.
(Excerpt) Read more at medicalxpress.com ...
These studies are a waste of time & $$. They will NEVER map the microbiome with these methods.
Worse, with all the toxins people consume on a daily basis, it’s a totally moot point except for those who consume food/water 100% toxin free (perhaps 0.05% of the population, if even, and NOT including yours truly).
c. butyricum miyari 588 has long been used in several Asian nations as a prophylaxis against c. difficile, which has been described as “cholera’s younger brother”, which gives a person about a month of chronic diarrhea.
Very easy to spread, it tends to afflict hospitals, nurses, patients, and others with a month long misery.
The brand name of the Japanese company that makes an oral form of c. butyricum miyari 588 is called “Miyarisin”.
It can be purchased on ebay, made in Japan, but shipping to the US can take three weeks. Beats the heck out of having a C. difficile infection.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.